Proteomics International Laboratories Ltd
ASX:PIQ
Intrinsic Value
Proteomics International Laboratories Ltd. is a medical technology company which operates at the forefront of predictive diagnostics and bio-analytical services. [ Read More ]
The intrinsic value of one
PIQ
stock under the Base Case scenario is
0.616
AUD.
Compared to the current market price of 1.095 AUD,
Proteomics International Laboratories Ltd
is
Overvalued by 44%.
PIQ's market price has consistently been higher than its intrinsic value.This persistent overvaluation suggests the market may be overly optimistic about
PIQ or that its price is influenced by factors unrelated to fundamentals.
Proteomics International Laboratories Ltd's market capitalization is 134m AUD.
PIQ stock price is 1.095 AUD.
PIQ stock (0.616 AUD) is 44% less than its price (1.095 AUD).
PIQ has upside potential of 29% compared to the average analyst price target.
Open Wall St Estimates
PIQ's Revenue has been growing by 4% per year for the last 3 years.
PIQ's Revenue has dropped by 22% over the past 12 months.
PIQ's ROE (Return on Equity) has significantly decreased in the last 3 years from -37% to -94%, and is approaching profitability.
PIQ's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from -120% to -329%, and is approaching profitability.
PIQ has negative Operating Income for the last twelve months.
PIQ has negative Net Income for the last twelve months.
PIQ's ROE (Return on Equity) for the past 12 months is negative and is equal to -94%.
PIQ's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -329%.
PIQ's Revenue is forecast to grow at a rate of 117% per year over the next 3 years.
PIQ has negative Free Cash Flow for the last twelve months.
PIQ's D/E (Debt to Equity) is very low and is equal to 0.
PIQ has negative three-year average ROE (Return on Equity): -76%. The company is not efficient at transforming stockholders' equity into net income.
PIQ has negative three-year average ROIC (Return on Invested Capital): -224%. The company is not efficient at using invested capital to generate operating income.
PIQ's short-term assets (5m AUD) exceed its short-term liabilties (1m AUD).
PIQ's long-term assets (7m AUD) exceed its long-term liabilties (2m AUD).
PIQ has negative Net Debt. This means that the company has more cash and short-term investments (5m AUD) than debt (11k AUD).
PIQ's Altman Z-Score is very high and is equal to 33.24.
Valuation Backtest
Proteomics International Laboratories Ltd
Run backtest to discover the historical profit from buying and selling
PIQ
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Proteomics International Laboratories Ltd
Balance Sheet Decomposition
Proteomics International Laboratories Ltd
| Current Assets | 5.2m |
| Cash & Short-Term Investments | 5m |
| Receivables | 76.7k |
| Other Current Assets | 129.6k |
| Non-Current Assets | 1.8m |
| PP&E | 1.8m |
| Intangibles | 1k |
| Current Liabilities | 1.2m |
| Accounts Payable | 387.2k |
| Other Current Liabilities | 806.7k |
| Non-Current Liabilities | 401.3k |
| Long-Term Debt | 11k |
| Other Non-Current Liabilities | 390.3k |
Earnings Waterfall
Proteomics International Laboratories Ltd
|
Revenue
|
1.4m
AUD
|
|
Operating Expenses
|
-7.4m
AUD
|
|
Operating Income
|
-6m
AUD
|
|
Other Expenses
|
100.5k
AUD
|
|
Net Income
|
-5.9m
AUD
|
Free Cash Flow Analysis
Proteomics International Laboratories Ltd
PIQ Profitability Score
Profitability Due Diligence
Proteomics International Laboratories Ltd's profitability score is 18/100. The higher the profitability score, the more profitable the company is.
Score
Proteomics International Laboratories Ltd's profitability score is 18/100. The higher the profitability score, the more profitable the company is.
PIQ Solvency Score
Solvency Due Diligence
Proteomics International Laboratories Ltd's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Score
Proteomics International Laboratories Ltd's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PIQ Price Targets Summary
Proteomics International Laboratories Ltd
According to Wall Street analysts, the average 1-year price target for
PIQ
is 1.408 AUD
with a low forecast of 1.394 AUD and a high forecast of 1.449 AUD.
Shareholder Return
PIQ Price
Proteomics International Laboratories Ltd
| Average Annual Return | 56.03% |
| Standard Deviation of Annual Returns | 95.77% |
| Max Drawdown | -47% |
| Market Capitalization | 134m AUD |
| Shares Outstanding | 130 893 000 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Proteomics International Laboratories Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Proteomics International Laboratories Ltd. is a medical technology company which operates at the forefront of predictive diagnostics and bio-analytical services. The company is headquartered in Nedlands, Western Australia. The company went IPO on 2015-04-16. The firm is engaged in predictive diagnostics and bio-analytical services. The firm specializes in proteomics, the study of the structure and function of proteins. The firm focuses on developing and commercializing diagnostic tests for chronic diseases. The firm operates in three business units unified by a technology platform: PromarkerD, Diagnostics and Analytical Services. PromarkerD is a predictive diagnostic test for diabetic kidney disease, a progressive disorder found in one in three adults with diabetes. Diagnostics includes Promarker platform, used to discover, verify, and analytically validate the panel of protein biomarkers for diabetic kidney disease. Analytical Services includes proteomics-based technology platform, used to test, and validate the protein composition of a wide and varied range of products.
Contact
IPO
Employees
Officers
The intrinsic value of one
PIQ
stock under the Base Case scenario is
0.616
AUD.
Compared to the current market price of 1.095 AUD,
Proteomics International Laboratories Ltd
is
Overvalued by 44%.
You don't have any saved screeners yet
